Molecular Insight Pharmaceuticals, Inc. and MDS Nordion Enter Manufacturing Agreement for Cardiac Molecular Imaging Pharmaceutical Zemiva™

Cambridge, MA, February 16, 2006 – Molecular Insight Pharmaceuticals, Inc. today announced that it has entered into a six-year, renewable agreement for the commercial manufacture and supply of Zemiva™ (iodofiltic acid I 123). Zemiva™ is a molecular imaging pharmaceutical under development by Molecular Insight for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. Molecular Insight's initial target market for Zemiva™ is for the diagnosis of cardiac ischemia in the emergency department setting, where an estimated five to eight million patients in the United States present each year with chest pain. Further terms of the agreement were not disclosed.

"We believe that this is an important agreement for the long-term commercial supply of Zemiva™, our lead product candidate," said David Barlow, Chairman and Chief Executive Officer of Molecular Insight. "MDS Nordion has been an outstanding partner during Zemiva™'s clinical development program and we look forward to continuing to work with the company."

About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics. The company's product candidates target markets with significant unmet needs in cardiology, oncology, and neurology. Molecular Insight's lead product candidate, Zemiva™ (iodofiltic acid I 123) is in development as a molecular imaging pharmaceutical for the diagnosis of insufficient blood flow to the heart, or cardiac ischemia. The company's second lead product candidate, Ultratrace™ MIBG, is in development for the diagnosis and treatment of neuroendocrine tumors. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts. The company’s website is: www.molecularinsight.com.

Contact:
Priscilla Harlan
Vice President, Corporate Communications
Molecular Insight Pharmaceuticals, Inc.
(617) 492-5554